HRTX - Heron Therapeutics reports Q3 results affirms FY oncology care franchise revenue guidance
- Heron Therapeutics press release ( NASDAQ: HRTX ): Q3 GAAP EPS of -$0.38 in-line.
- Revenue of $26.56M (+14.3% Y/Y) misses by $0.4M .
- Heron currently expects FY 2022 net product sales for the oncology care franchise of $93M to $95M, unchanged from prior outlook.
- As of September 30, 2022, Heron had cash, cash equivalents and short-term investments of $121.7M, compared to $157.6M as of December 31, 2021.
For further details see:
Heron Therapeutics reports Q3 results, affirms FY oncology care franchise revenue guidance